Clinical Trials Logo

Filter by:
NCT ID: NCT03578809 Recruiting - Clinical trials for ST Elevation Myocardial Infarction

A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction

REAL-TIMI 63B
Start date: June 5, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2b randomized, blinded, placebo controlled study to evaluate the efficacy, safety, PK/pharmacodynamic, and immunogenicity of repeat doses of MEDI6012 in adult subjects presenting with acute STEMI (ST segment elevation myocardial infarction). The study will enrol subjects presenting with acute STEMI who are planned for primary percutaneous coronary intervention (pPCI). For all subjects, an end of study CMR will be performed at 10-12 weeks (70-84 days following Dose 1). A subset of subjects will also undergo an index and an end of study CTA.

NCT ID: NCT03557398 Completed - Clinical trials for Vulvovaginal Atrophy

Efficacy and Safety of HYDEAL-D Vaginal Pessaries Application on the Treatment of Vaginal Atrophy in Post-menopause Women

Start date: November 29, 2017
Phase: N/A
Study type: Interventional

This study evaluates the efficacy and safety of hyaluronic acid derivative based vaginal pessaries for the treatment of symptoms of vulvo-vaginal atrophy in post-menopausal women.

NCT ID: NCT03521037 Recruiting - Neoplasms Clinical Trials

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

Start date: March 31, 2018
Phase: Phase 1
Study type: Interventional

Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the NCI-ODWG criteria. Patients in Group 1 and Group 2 may be enrolled in parallel, with preferential enrollment of Group 2 patients before Group 1 patients. The study will consist of 2 parts: a single-dose PK part (Part I) and a continuous rucaparib treatment part (Part II).

NCT ID: NCT03511924 Recruiting - Clinical trials for Chronic Kidney Disease Requiring Chronic Dialysis

Intradialytic Resistance Training in Haemodialysis Patients

IRTHEP
Start date: January 11, 2018
Phase: N/A
Study type: Interventional

The study will investigate the effects of an intradialytic resistance training on microRNA´s expression and muscle strength in haemodialysis patients.

NCT ID: NCT03499288 Recruiting - Cerebral Palsy Clinical Trials

Profiling Children and Youth With Cerebral Palsy in Relation to Feeding and Nutrition

Purple-N
Start date: April 11, 2017
Phase:
Study type: Observational

HCPs will complete questionnaires about their patients with Cerebral Palsy (CP) and invite parents/caregivers of these patients to fill in questionnaires as well. Questionnaires include questions on individualized treatment, nutritional profile and management, and patient characteristics.

NCT ID: NCT03499223 Recruiting - Diabetes Mellitus Clinical Trials

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

Start date: April 20, 2018
Phase: Phase 2
Study type: Interventional

This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST), in subjects with central-involved diabetic macular oedema (CI-DME).

NCT ID: NCT03496298 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Effect of Efpeglenatide on Cardiovascular Outcomes

AMPLITUDE-O
Start date: April 27, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: -To demonstrate that, efpeglenatide doses 1 and 2 is noninferior to placebo on 3-point major adverse cardiac event (MACE) in Type 2 diabetes mellitus (T2DM) patients at high cardiovascular (CV) risk. Secondary Objectives: - To demonstrate that efpeglenatide doses 1 and 2 is superior to placebo in T2DM patients with high CV risk on the following parameters: - 3-point MACE. - Expanded CV outcome. - Composite outcome of new or worsening nephropathy. - To assess the safety and tolerability of efpeglenatide doses 1 and 2, both added to standard of care in T2DM patients at high CV risk.

NCT ID: NCT03495102 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

AWARD-11
Start date: April 5, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.

NCT ID: NCT03493997 Recruiting - Prostate Cancer Clinical Trials

Multicentre International STudy for the Prevention With Ialuril® of Radio-induced Cystitis (MISTIC)

MISTIC
Start date: April 4, 2017
Phase: Phase 2
Study type: Interventional

The study is randomized and it will be conducted in the field of routine clinical practice. A total of 100 consecutive patients planned to receive radiotherapy for prostate cancer will be enrolled. The patients will enter the study as controls (50 patients that won't receive any experimental IMP) or as treated-group (50 patients that will be also treated with the experimental IMPs, Ialuril® and Ialuril® Soft Gels) according to a predefined, centre-specific randomization.

NCT ID: NCT03484065 Recruiting - Clinical trials for Afibrinogenemia, Congenital

Quality of Life in Patients With Congenital Afibrinogenemia

QualyAFIB
Start date: June 2016
Phase:
Study type: Observational

The aim of this observational study is to evaluate the quality of life in patients with congenital afibrinogenemia using the Haemo-QoL SF for kids and the Haem-A-QoL for adult patients.